A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S, Sato T, Kuroda H, Nagamachi Y, Iyama S, Fujimi A, Kamihara Y, Konuma Y, Yoshida M, Tatekoshi A, Hashimoto A, Horiguchi H, Ono K, Murase K, Takada K, Miyanishi K, Kobune M, Hirayama Y, Kato J.
Ibata S, et al. Among authors: kato j.
Cancer Chemother Pharmacol. 2016 Nov;78(5):1041-1049. doi: 10.1007/s00280-016-3163-y. Epub 2016 Oct 13.
Cancer Chemother Pharmacol. 2016.
PMID: 27738809
Free PMC article.
Clinical Trial.